IMS: Pharma marketing needs $15B overhaul

You may think that Big Pharma has remodeled its promotional efforts quite enough, thank you. After all, companies have shed thousands of sales reps, in a big about-face from its previous boots-on-the-ground buildup. But IMS Health says drugmakers need an even bigger overhaul.

The pharma-market analysis firm says the industry should re-deploy about $15 billion in promotional spending because--to put it bluntly--those dollars aren't yielding enough sales. Instead of viewing doctors' offices as ground zero for most marketing efforts, drugmakers should broaden their focus to include drug-benefit plans. Managed care companies have lots more clout these days, using their formularies to guide members toward less expensive drugs--even if a physician has prescribed a costlier alternative.

Plus, companies shouldn't simply home in on clinical efficacy when promoting their drugs. They should tout cost-effectiveness, too, the IMS consultants said. And new technology, such as online detailing, can be more efficient than traditional sales detailing.

- see the Dow Jones story

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.